Handelsbanken Fonder’s PMV Pharmaceuticals PMVP Stock Holding History

Handelsbanken Fonder’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,000	Closed	-$205K	–	1691
2021 Q2	$205K	Buy	+6,000	New	+$200K	﹤0.01%	1693

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Handelsbanken Fonder's PMVP Position: Q3 2021 in Review

Handelsbanken Fonder sold out of PMV Pharmaceuticals (PMVP) in Q3 2021, closing a stake of 6,000 shares — an estimated $205K sold.

Handelsbanken Fonder first reported a position in PMVP in Q2 2021 and held it in 1 quarter. The position peaked at $205K in Q2 2021. 92 funds tracked by Wall St. Rank hold PMVP as of Q3 2021.

Handelsbanken Fonder reported no remaining PMV Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Handelsbanken Fonder sold 6,000 PMV Pharmaceuticals shares in Q3 2021, an estimated $205K.
Handelsbanken Fonder first reported a position in PMV Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Handelsbanken Fonder's PMV Pharmaceuticals position peaked at $205K in Q2 2021.
92 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2021.

Based on Handelsbanken Fonder's 13F filing for Q3 2021, filed 10 Nov 2021.